Download PDF
Thromb Haemost 1998; 79(02): 383-388
DOI: 10.1055/s-0037-1614996
Letters to the Editor
Schattauer GmbH

Effect of SR121566A, a Potent GP IIb-IIIa Antagonist on Platelet-mediated Thrombin Generation In Vitro and In Vivo

J. P. Herault
1   From the Haemobiology Research Department, Sanofi Recherche, Toulouse, France
,
V. Peyrou
1   From the Haemobiology Research Department, Sanofi Recherche, Toulouse, France
,
P. Savi
1   From the Haemobiology Research Department, Sanofi Recherche, Toulouse, France
,
A. Bernat
1   From the Haemobiology Research Department, Sanofi Recherche, Toulouse, France
,
J. M. Herbert
1   From the Haemobiology Research Department, Sanofi Recherche, Toulouse, France
› Author Affiliations
Further Information

Publication History

Received 27 August 1997

Accepted 03 October 1997

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

The effect of SR121566A, a new non-peptide GP IIb-IIIa antagonist was studied in vitro with regard to thrombin generation in platelet rich plasma and in vivo on stasis-induced venous thrombosis in the rabbit. SR121566A inhibited ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50 values of 46 ± 7.5, 56 ± 6 and 42 ± 3 nM, respectively. In the same experimental conditions, SR121566A strongly inhibited thrombin generation triggered by low concentrations of tissue factor. SR121566A reduced in a dose-dependent manner both the area under the curve and the thrombin peak concentration but did not affect the lag phase (defined as the time until 10 nM thrombin was generated). Aspirin (100 µg/ml) did not affect thrombin generation.

One hour after intravenous administration to rabbits, SR121566A exhibited a potent ex vivo inhibitory effect against ADP-, arachidonic acid- and collagen-induced platelet aggregation. The ID50 were 0.6 ± 0.25, 0.7 ± 0.08 and 0.13 ± 0.08 mg/kg, respectively. The ability of aspirin and SR121566A to affect venous stasis was determined in a stasis-induced venous thrombosis model in rabbits under high and low thrombogenic challenges. While aspirin was ineffective in both conditions, SR121566A significantly inhibited thrombus formation under low thrombogenic challenge demonstrating for the first time that a potent non-peptide platelet GP IIb-IIIa antagonist inhibits thrombin generation in vivo and exhibits a strong antithrombotic effect with regard to stasis-induced venous thrombosis. These results therefore confirm the existence of a close relationship between platelet activation and thrombin generation leading to blood coagulation but also emphasise the key role of platelets in the development of venous thrombosis, most likely through activation of the GP IIb-IIIa complex.

 

  • References

  • 1 Walsh PM, Schmaier AH. Platelet-coagulant protein interactions. In: Hemostasis & Thrombosis: Basic principles and clinical practice. 3rd ed. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. JB Lippicott Co; Philadelphia: 1994: 629-51.
    Google Scholar
  • 2 Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug. Hum Pathol 1987; 18: 111-32.
    CrossrefPubMedGoogle Scholar
  • 3 Bevers EM, Comfurius P, Van Rijn JLML, Henker C, Zwaal RFA. Generation of prothrombin-converting activity and the exposure of phosphatidyl serine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36.
    CrossrefPubMedGoogle Scholar
  • 4 Bevers EM, Comfurius P, Zwaal RFA. Mechanisms involved in platelets procoagulant response. In: Mechanism of platelet activation and control. Authi KS. et al., eds. Plenum Publishing Corp; New York: 1994: 195-207.
    Google Scholar
  • 5 Bernat A, Vallée E, Maffrand JP, Gordon JL. The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat. Thromb Res 1988; 52: 65-70.
    CrossrefPubMedGoogle Scholar
  • 6 Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-6.
    PubMedGoogle Scholar
  • 7 Bernat A, Vallée E, Maffrand JP, Roncucci R. Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis. Thromb Res 1985; 37: 279-85.
    CrossrefPubMedGoogle Scholar
  • 8 Maffrand JP, Vallée E, Bernat A, Delebassée D, Millou E, Tissinier A, Roncucci R. Animal pharmacology of PCR 4099, a new thienopyridine compound. Thromb Haemost 1985; 54: 789.
    PubMedGoogle Scholar
  • 9 Reverter JC, Beguin S, Kessels R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/ human chimeric 7E3 antibody. J Clin Invest 1996; 98: 863-74.
    CrossrefPubMedGoogle Scholar
  • 10 Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb-IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528-35.
    CrossrefPubMedGoogle Scholar
  • 11 Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 coordinates the activation of factor Xa on stimulated cells on monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 1988; 85: 7462-6.
    CrossrefPubMedGoogle Scholar
  • 12 Altieri DC, Edgington TS. The saturable high affinity association of factor Xa to ADP-stimulated monocytes defines a novel function of the MAC-1 receptor. J Biol Chem 1988; 263: 7007-15.
    PubMedGoogle Scholar
  • 13 Savi P, Badorc A, Lale A, Bordes MF, Bornia J, Labouret C, Bernat A, De Cointet P, Hoffmann P, Maffrand JP, Herbert JM. SR 121787, a new orally active fibrinogen receptor antagonist. Submitted for publication.
    PubMedGoogle Scholar
  • 14 Hoffmann P, Bernat A, Savi P, Herbert JM. Antiplatelet and antithrombotic efficacy of SR 121787, a non-peptide orally active GpIIb/IIIa antagonist, in rabbits. Comparison to clopidogrel and aspirin. J Cardiovasc Pharm. 1997 in press.
    PubMedGoogle Scholar
  • 15 Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond.) 1962; 194: 927-9.
    PubMedGoogle Scholar
  • 16 Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Peyrou V, Lormeau JC, Hérault JP, Boneu B, Herbert JM. Long-term persistence of low molecular weight material with anti-factor Xa activity contributes to the anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit. Blood Coag Fibrinol 1997; 8: 175-84.
    CrossrefPubMedGoogle Scholar
  • 18 Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Herbert JM, Hérault JP, Bernat A, Van Amsterdam RGM, Vogel GMT, Lormeau JC, Petitou M, Meuleman DG. Biochemical and Pharmacological Properties of SANORG 32701 – Comparison with the “Synthetic pentasaccharide” (SR 90107/0rg 31540) and Standard Heparin. Circ Res 1996; 79: 590-600.
    CrossrefPubMedGoogle Scholar
  • 20 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Anti-thrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-98.
    CrossrefPubMedGoogle Scholar
  • 21 Dol F, Gaich C, Bernat A, Mauran G, Herbert JM. Effect of clopidogrel on thrombin generation in the rat. Thromb Res 1992; 65: S160 (abst.).
    PubMedGoogle Scholar
  • 22 Weiss HJ, Turitto VT, Baumgartner HG. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelets defects. J Clin Invest 1986; 78: 1072-82.
    CrossrefPubMedGoogle Scholar
  • 23 Kessels H, Beguin S, Andree H, Henker HC. Measurement of thrombin generation in whole blood. The effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Coller BS. Inhibitors of the platelet glycoproteinIIb/IIIa receptor as a conjunctive therapy for coronary artery disease. Coron Artery Dis 1992; 3: 1016-29.
    CrossrefPubMedGoogle Scholar
  • 25 Cook NS, Kottirsch G, Zerwes HG. Platelet glycoprotein IIb/IIIa antagonsist. Drug Future 1994; 19: 135-59.
    PubMedGoogle Scholar
  • 26 Cadroy Y, Hanson SR, Andrews BK, Marzec UM, Evatt BL, Kunichi TJ, Montgomery RR, Harker LA. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 1994; 83: 3218-24.
    PubMedGoogle Scholar
  • 27 Moliterno DJ, Califf RM, Aguire FV, Anderson K, Sigmon KN, Topol EJ. Effect of platelet GP IIb-IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC study). Am J Cardiol 1995; 87: 559-62.
    PubMedGoogle Scholar
  • 28 Wessler S. Thrombosis in the presence of vascular stasis. Am J Med 1962; 33: 648-66.
    CrossrefPubMedGoogle Scholar
  • 29 Wessler S, Gitel SN, Bank H, Martinowitz U, Stephenson RC. An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits. Thromb Haemost 1978; 40: 486-98.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Vogel GM, Meuleman DG, Bourgondien FG, Hobbelen PM. Comparison of two experimental thrombosis models in rats – effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410.
    CrossrefPubMedGoogle Scholar